BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 1614411)

  • 1. [3H]pBC 264, a suitable probe for studying cholecystokinin-B receptors: binding characteristics in rodent brains and comparison with [3H]SNF 8702.
    Durieux C; Ruiz-Gayo M; Corringer PJ; Bergeron F; Ducos B; Roques BP
    Mol Pharmacol; 1992 Jun; 41(6):1089-95. PubMed ID: 1614411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new, highly selective CCK-B receptor radioligand ([3H][N-methyl-Nle28,31]CCK26-33): evidence for CCK-B receptor heterogeneity.
    Knapp RJ; Vaughn LK; Fang SN; Bogert CL; Yamamura MS; Hruby VJ; Yamamura HI
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1278-86. PubMed ID: 2262906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the binding of [3H]L-365,260: a new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand.
    Chang RS; Chen TB; Bock MG; Freidinger RM; Chen R; Rosegay A; Lotti VJ
    Mol Pharmacol; 1989 Jun; 35(6):803-8. PubMed ID: 2733696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors.
    Boteju LW; Nikiforovich GV; Haskell-Luevano C; Fang SN; Zalewska T; Stropova D; Yamamura HI; Hruby VJ
    J Med Chem; 1996 Sep; 39(20):4120-4. PubMed ID: 8831778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo binding affinities of cholecystokinin agonists and antagonists determined using the selective CCKB agonist [3H]pBC 264.
    Durieux C; Ruiz-Gayo M; Roques BP
    Eur J Pharmacol; 1991 Dec; 209(3):185-93. PubMed ID: 1797561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.
    Blommaert AG; Dhôtel H; Ducos B; Durieux C; Goudreau N; Bado A; Garbay C; Roques BP
    J Med Chem; 1997 Feb; 40(5):647-58. PubMed ID: 9057851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclic cholecystokinin analogues that are highly selective for rat and guinea pig central cholecystokinin receptors.
    Rodriguez M; Lignon MF; Galas MC; Amblard M; Martinez J
    Mol Pharmacol; 1990 Sep; 38(3):333-41. PubMed ID: 1698251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33).
    Lin CW; Holladay MW; Barrett RW; Wolfram CA; Miller TR; Witte D; Kerwin JF; Wagenaar F; Nadzan AM
    Mol Pharmacol; 1989 Dec; 36(6):881-6. PubMed ID: 2601685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of SNF 9007, a novel cholecystokinin/opoid ligand in mouse ileum in vitro: evidence for involvement of cholecystokininA and cholecystokininB receptors in regulation of ion transport.
    Rao RK; Levenson S; Fang SN; Hruby VJ; Yamamura HI; Porreca F
    J Pharmacol Exp Ther; 1994 Feb; 268(2):1003-9. PubMed ID: 8113956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of cholecystokinin receptors and messenger RNA expression in rat pancreas: evidence for expression of cholecystokinin-A receptors but not cholecystokinin-B (gastrin) receptors.
    Zhou W; Povoski SP; Bell RH
    J Surg Res; 1995 Mar; 58(3):281-9. PubMed ID: 7533864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the binding of [3H]-(+/-)-L-364,718: a new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors.
    Chang RS; Lotti VJ; Chen TB; Kunkel KA
    Mol Pharmacol; 1986 Sep; 30(3):212-7. PubMed ID: 3018478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological activity of novel, potent and long-acting analogs of AC-CCK-7 with high affinity for peripheral (type A) receptors.
    Danho W; Makofske RC; Swistok J; Michalewsky J; Gabriel T; Marks N; Berg MJ; Baird L; Geiler V; Mackie G
    Pept Res; 1991; 4(2):59-65. PubMed ID: 1815779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of cholecystokinin analogs in which the Asp-Phe-NH2 moiety has been replaced by a 3-amino-7-phenylheptanoic acid or a 3-amino-6-(phenyloxy)hexanoic acid.
    Amblard M; Rodriguez M; Lignon MF; Galas MC; Bernad N; Artis-Noël AM; Hauad L; Laur J; Califano JC; Aumelas A
    J Med Chem; 1993 Oct; 36(20):3021-8. PubMed ID: 7692048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study of induced effects by selective CCKB agonists cholecystokinin in the nociception and behavior in rodents].
    Dauge V; Derrien M; Durieux C; Noble F; Corringer PJ; Roques BP
    Therapie; 1992 Nov; 47(6):531-9. PubMed ID: 1301645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of cholecystokinin receptor sites in guinea-pig cortical membranes using [125I]Bolton Hunter-cholecystokinin octapeptide.
    Lin CW; Miller T
    J Pharmacol Exp Ther; 1985 Mar; 232(3):775-80. PubMed ID: 2983069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of behavioral and electrophysiological responses induced by selective stimulation of CCKB receptors by using a new highly potent CCK analog, BC 264.
    Dauge V; Bohme GA; Crawley JN; Durieux C; Stutzmann JM; Feger J; Blanchard JC; Roques BP
    Synapse; 1990; 6(1):73-80. PubMed ID: 2399491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and binding affinities of cyclic and related linear analogues of CCK8 selective for central receptors.
    Charpentier B; Dor A; Roy P; England P; Pham H; Durieux C; Roques BP
    J Med Chem; 1989 Jun; 32(6):1184-90. PubMed ID: 2724293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photoaffinity labeling of rat pancreatic cholecystokinin type A receptor antagonist binding sites demonstrates the presence of a truncated cholecystokinin type A receptor.
    Poirot SS; Escrieut C; Dufresne M; Martinez J; Bouisson M; Vaysse N; Fourmy D
    Mol Pharmacol; 1994 Apr; 45(4):599-607. PubMed ID: 8183238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulation of delta-opioid receptors reduces the in vivo binding of the cholecystokinin (CCK)-B-selective agonist [3H]pBC 264: evidence for a physiological regulation of CCKergic systems by endogenous enkephalins.
    Ruiz-Gayo M; Durieux C; Fournié-Zaluski MC; Roques BP
    J Neurochem; 1992 Nov; 59(5):1805-11. PubMed ID: 1357099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin.
    Gigoux V; Maigret B; Escrieut C; Silvente-Poirot S; Bouisson M; Fehrentz JA; Moroder L; Gully D; Martinez J; Vaysse N; Fourmy AD
    Protein Sci; 1999 Nov; 8(11):2347-54. PubMed ID: 10595537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.